ECElin S. Cho

Elin S. Cho

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elin S. Cho has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • FDA Approval Summary: Lifileucel for Unresectable or Metastatic Melanoma Previously Treated with an Anti–PD-1–Based Immunotherapy

    by Lianne Hu, Chaohong Fan, Peter Bross, Asha Das, Elin S. Cho, Karin M. Knudson, Million Tegenge, Qianmiao Gao, Jamie R. Brewer, Marc R. Theoret, et al.

    On February 16, 2024, the FDA granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1–blocking antibody and, if BRAF V600 mutation positive, a BRAF inhibitor with or without an MEK inhibitor. Lifileucel is the first tumor-derived T-cell therapy approved by the FDA. In the phase II single-arm trial, Study C-144-01, that served as the basis for approval, the objective response rate among patients treated with lifileucel within FDA-approved dose range (7.5 × 109 to 72 × 109 viable cells, n = 73) in the primary efficacy cohort was 31.5% (95% confidence interval, 21.1%–43.4%), including three (4.1%) complete responses and 20 (27.4%) partial responses. The median duration of response was not reached (95% confidence interval, 4.1 months–not reached). Among the responders (n = 23), 56.5%, 47.8%, and 43.5% maintained durable responses at 6, 9, and 12 months, respectively. Among all patients who received lifileucel (n = 156) in the primary and supportive cohorts of Study C-144-01, 95.5% of patients experienced at least one Grade 3 treatment-emergent adverse event and 87.8% experienced at least one Grade 4 treatment-emergent adverse event. Lifileucel labeling includes a Boxed Warning for treatment-related mortality, prolonged severe cytopenia, severe infection, cardiopulmonary impairment, and renal impairment.


  • FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4–Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy

    by Katherine K. Barnett, Abigail R. Johnson, Asha Das, Ching-Hsien J. Lee, Cong Wang, Xiaofei Wang, Elin S. Cho, Paul G. Kluetz, Lola A. Fashoyin-Aje

    On August 1, 2024, the FDA granted accelerated approval to afamitresgene autoleucel, a melanoma-associated antigen A4 (MAGE-A4)–directed genetically modified autologous T-cell immunotherapy, for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, who are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive, and whose tumors express MAGE-A4 as determined by FDA-approved or cleared companion diagnostic devices. Approval was based on results from the phase II, single-arm, open-label, multicenter Study ADP-0044-002. Patients received a single dose of afamitresgene autoleucel following lymphodepleting chemotherapy. Of the 44 efficacy-evaluable patients, the overall response rate was 43.2% (95% confidence interval, 28.4–59.0), with complete response in two patients (4.5%). The median duration of response was 6.0 months (95% confidence interval, 4.6–not reached) with a median follow-up of 21.9 months. Among the 44 patients, cytokine release syndrome occurred in 75% (grade ≥3, 2%), warranting a boxed warning. Grade ≥3 infections occurred in 14% of patients, and prolonged severe cytopenias also occurred. One patient developed grade 1 immune effector cell–associated neurotoxicity, and one patient developed Epstein–Barr virus–positive lymphoproliferative disease. Notably, during review of this application, the FDA identified issues with data quality and study conduct that prompted an independent re-review of imaging assessments. The results of the re-review were the basis for the FDA’s determination of substantial evidence of effectiveness. This represents the first FDA approval of a T-cell receptor gene therapy. It is also the first FDA approval specifically for synovial sarcoma, representing a new treatment modality for this rare population that lacks effective therapies.